We sat down and spoke with with Rey Chern, Director, Engineering, Amgen; Lisa Sykes, Director of Quality Operations and Sterile Network, Merck; Bernard McGarvey, Senior Engineering Advisor, Eli Lilly and Company; Dan Mirica, Former Head of Global Logistics, Lonza Biologics; & Henrik Fröjdh, Associate Director Supply Chain Management, Merck & Co. on:

• Temperature-controlled industry
• The biggest disruptive technologies
• Collaboration within the industry

Email enquiry@iqpc.com to request the video link sent to you via email.

• Collaboration with carriers to keep temperatures within source conditions
• Challenges with the last mile & saving cost in quality investments
• Needs from data logging and RFID technology
  
  

Email enquiry@iqpc.com to request an emailed copy of the video.

We sat down with Dan Mirica, Former Head of Logistics, Lonza Biologics and discussed: 

• blockchain applications for the pharma supply chain
• challenges with drone implementation
• the emergence of self driving trucks in Europe
  

With a rise in precision medicines, high value shipments and emergingshipping routes, global biopharma industry spending on temperaturecontrolled products is expected to reach $15.7 billion in 2019.1 To ensure that companies are able to navigate this new product landscape and complex routes in a cost efficient and effective way, they must rely on specialized and trusted partners.

In this report, Pharma IQ explores how these trends will affect temperature control and logistics spending in the next 12 to 24 months. All the findings from our recent survey are presented and analysed below.